glenzocimab

Glenzocimab is a humanized monoclonal antibody fragment (Fab) that targets the human platelet glycoprotein VI (GPVI), a key receptor involved in platelet activation and thrombus formation. By binding to the D2 domain of GPVI, glenzocimab inhibits GPVI dimerization and its interactions with collagen and fibrin, thereby preventing downstream signaling required for clot growth and stability. This mechanism allows glenzocimab to function as an antithrombotic agent without significantly increasing bleeding risk. Glenzocimab is being developed primarily for use during the acute phase of ischemic stroke as an add-on therapy to thrombolysis, with or without mechanical thrombectomy. It is also under investigation for acute myocardial infarction and has been studied in SARS-CoV-2 acute respiratory disease[1][4][5][6][7].

Other names

Immunoglobulin g1, anti-(human platelet glycoprotein vi) fab fragment (humanized monoclonal act017 gamma1-chain), disulfide with humanized monoclonal act017 kappa-chain